Core Points - The meeting organized by the Shanxi Province Tianzhen County Market Supervision Bureau aimed to regulate the pharmaceutical market and combat illegal activities in drug circulation [1] - The meeting conveyed the requirements for the "Qingyuan" action and discussed typical cases of drug management violations [1] - Emphasis was placed on the legal responsibilities and severe consequences of non-compliance with drug management laws [1] Summary by Sections Regulatory Actions - The Tianzhen County Market Supervision Bureau will enhance enforcement checks under the "Qingyuan" action to maintain a high-pressure stance against illegal activities in drug management [2] - The meeting highlighted the need for pharmaceutical companies to conduct self-inspections and address potential risks in their operations [1] Compliance and Responsibilities - Pharmaceutical enterprises are urged to learn from case studies and fulfill their primary responsibilities, focusing on key areas such as procurement, storage, and prescription sales [1] - Companies must establish detailed problem lists and rectification accounts to ensure compliance within specified deadlines [1]

Core Viewpoint - The National Medical Products Administration (NMPA) has announced five typical cases of illegal activities in the pharmaceutical sector and issued compliance and consumer reminders [1] Group 1: Illegal Activities - Two cases involve illegal procurement of drugs through unauthorized channels, including a pharmacy in Guangdong that faced penalties of 1.3 million yuan and a pharmacy in Jiangxi that was fined 224,100 yuan for purchasing drugs from unqualified individuals [2] - A case in Zhejiang involved a pharmacy that failed to conduct proper prescription reviews when dispensing prescription drugs, resulting in a fine of 40,000 yuan [3] - An individual in Guangxi was penalized for selling unregistered medical products through WeChat, with fines totaling 17,400 yuan [3] - A clinic in Sichuan was found selling prohibited drugs online without permission, leading to a fine of 50,000 yuan [3] Group 2: Compliance and Consumer Reminders - The NMPA emphasizes that pharmaceutical businesses should purchase drugs from licensed manufacturers and maintain accurate sales records, adhering to quality management standards [4] - Consumers are advised to buy drugs from licensed pharmacies and to be cautious when purchasing online, ensuring that relevant licenses are displayed prominently [4] - It is recommended that consumers provide valid prescriptions when purchasing prescription drugs and report any illegal activities related to counterfeit or substandard drugs to regulatory authorities [4]